KT150 mg/ml

Established / FDA-Approved Uses

• Treatment of hypokalemia (low blood potassium) — KT 150 mg/ml is indicated for patients found to have hypokalemia with or without metabolic alkalosis, including cases due to diuretic therapy, vomiting, diarrhea, or inadequate dietary intake.
• Prevention of hypokalemia in patients at high risk of developing low potassium levels, such as those receiving potassium-losing (non-potassium-sparing) diuretics, digitalis therapy, or with conditions causing excessive potassium loss.

Guideline-Supported / Adjunct Uses

• As an adjunct in the management of diabetic ketoacidosis once insulin therapy has been initiated and serum potassium has started to fall.
• Correction of hypokalemia in patients on digoxin therapy, since low potassium increases the risk of digitalis toxicity.

KT 150 mg/ml is not indicated for patients who are not potassium-deficient, and routine potassium supplementation is not recommended for all diuretic users without documented or anticipated hypokalemia.

Each unit of KT 150 mg/ml contains KT 150 mg/ml USP/BP as the sole active ingredient. It is formulated as extended-release tablets or capsules, immediate-release oral solution/powder, effervescent tablets, and as a sterile concentrated solution for intravenous infusion (which must always be diluted before use). Strength is generally expressed in milliequivalents (mEq) of potassium, with common oral strengths equivalent to 8 mEq, 10 mEq, or 20 mEq per unit, and injectable concentrates commonly supplied as 10%, 15%, or 20% w/v solutions (approximately 1.34–2.68 mEq/mL).

KT 150 mg/ml is a mineral/electrolyte replacement product used to prevent and treat low levels of potassium in the blood (hypokalemia). Potassium is an essential intracellular cation required for normal nerve conduction, muscle contraction (including the heart), and maintenance of acid-base and fluid balance. KT 150 mg/ml is available in oral (tablet, capsule, powder, liquid) and intravenous forms, and is widely used in both hospital and outpatient settings, particularly in patients on long-term diuretic therapy.

KT 150 mg/ml belongs to the therapeutic class of Electrolytes and Minerals, specifically classified as a Potassium Replacement / Electrolyte Supplement.

Potassium is the principal intracellular cation in the body and plays a critical role in maintaining cell membrane electrical potential, nerve impulse conduction, skeletal and cardiac muscle contractility, renal tubular function, and intracellular osmolality. KT 150 mg/ml works by directly replenishing potassium and chloride ions that have been depleted, restoring normal serum potassium concentration (typically 3.5–5.0 mEq/L) and thereby normalizing the resting membrane potential of excitable tissues such as cardiac and skeletal muscle. Because potassium is actively transported into cells and excreted primarily by the kidneys, correction of a potassium deficit requires appropriate dosing over time along with monitoring, as extracellular (serum) levels do not always reflect the true total body deficit.

Take oral KT 150 mg/ml tablets/capsules whole (do not crush or chew extended-release forms) with meals and a full glass of water to reduce stomach upset. Dissolve powder, effervescent, or liquid forms fully in water/juice before drinking. Intravenous KT 150 mg/ml must always be diluted and infused slowly under medical supervision with cardiac monitoring — never given undiluted or by rapid injection.

Clinically Significant Interactions

• Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene): concurrent use with KT 150 mg/ml increases the risk of significant hyperkalemia due to additive potassium retention; combination should generally be avoided or requires close potassium monitoring.
• ACE inhibitors and Angiotensin Receptor Blockers (ARBs): reduce aldosterone-mediated potassium excretion, increasing hyperkalemia risk when combined with KT 150 mg/ml.
• NSAIDs: may reduce renal potassium excretion and renal function, increasing hyperkalemia risk with concurrent KT 150 mg/ml use.
• Non-selective beta-blockers: may impair cellular potassium uptake, increasing serum potassium levels during KT 150 mg/ml therapy.
• Salt substitutes and potassium-containing supplements/foods: additive potassium intake increases hyperkalemia risk and should be used cautiously alongside KT 150 mg/ml.
• Digoxin: hypokalemia increases susceptibility to digitalis toxicity; correcting potassium with KT 150 mg/ml is important, but potassium levels should be monitored closely as over-correction can also affect cardiac rhythm.

Common Side Effects

• Nausea, vomiting
• Abdominal discomfort/pain
• Diarrhea or loose stools
• Flatulence

Serious Side Effects (seek medical attention)

• Gastrointestinal ulceration, bleeding, or perforation (rare, mainly with solid oral dosage forms)
• Signs of hyperkalemia: tingling/numbness in hands, feet, or lips; muscle weakness or paralysis; irregular heartbeat, palpitations, or slow heart rate
• Pain, redness, or swelling at the intravenous injection site (with IV administration)

Patients experiencing any signs of hyperkalemia while taking KT 150 mg/ml should seek immediate medical attention.

Pregnancy: Potassium is a normal dietary and physiological requirement during pregnancy, and KT 150 mg/ml may be used when clinically indicated to correct documented hypokalemia. However, it should be used only under medical supervision, with the dose individualized and potential benefit weighed against risk, and serum potassium monitored, since both hypokalemia and hyperkalemia during pregnancy can be harmful. Consult a physician before use during pregnancy.

Lactation: Potassium is a normal constituent of breast milk, and KT 150 mg/ml is generally considered acceptable during breastfeeding when used at recommended doses for a genuine clinical indication. Nonetheless, a physician should be consulted, and the nursing infant monitored, before initiating KT 150 mg/ml during lactation.

Warnings

• High-Alert Medication: Concentrated KT 150 mg/ml for injection must never be administered undiluted or as a rapid intravenous push — doing so can cause immediate, fatal cardiac arrhythmias and cardiac arrest. It must always be diluted appropriately and infused slowly with continuous cardiac (ECG) monitoring in a supervised clinical setting.
• Hyperkalemia risk: Use with caution in patients with renal impairment, or those taking potassium-sparing diuretics, ACE inhibitors/ARBs, or other drugs that raise serum potassium (see Interactions); periodic monitoring of serum potassium is required, especially with dose changes.
• Gastrointestinal ulceration: Solid oral dosage forms of KT 150 mg/ml have been associated with GI ulceration, bleeding, and perforation; take with food and a full glass of water/liquid, and discontinue and seek medical attention if severe abdominal pain, vomiting, GI bleeding, or distension occurs.
• Use with caution in patients with cardiac disease, especially those on digoxin, due to the interplay between potassium levels and cardiac conduction.
• Correct any coexisting metabolic acid-base disturbance under medical guidance, as it can affect potassium distribution.

Periodic monitoring of serum potassium, renal function, and acid-base status is recommended during KT 150 mg/ml therapy, particularly during dose adjustments.

Overdose of KT 150 mg/ml can cause hyperkalemia, which may be life-threatening. Symptoms and signs include tingling of extremities, muscle weakness or paralysis, confusion, and cardiac effects such as irregular heartbeat, heart block, or cardiac arrest, which can occur without significant warning signs. Overdose of KT 150 mg/ml is a medical emergency — seek immediate medical attention or contact emergency services/poison control if an overdose is suspected. Do not attempt to manage a suspected overdose at home; treatment requires hospital-based monitoring (ECG) and may include specific medical interventions to lower serum potassium.

Store KT 150 mg/ml at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze injectable concentrate solutions. Discard any unused diluted intravenous solution as directed by a healthcare professional.

Renal Impairment

KT 150 mg/ml should be used with caution and close monitoring in patients with renal impairment, as reduced potassium excretion increases the risk of hyperkalemia; it is contraindicated in severe renal impairment with oliguria/anuria (see Contraindications).

Hepatic Impairment

No specific dose adjustment is established for hepatic impairment alone; however, caution is warranted if hepatic disease is accompanied by fluid/electrolyte disturbances.

Elderly

Elderly patients often have reduced renal function and may be more susceptible to hyperkalemia; use KT 150 mg/ml cautiously with more frequent monitoring of serum potassium and renal function in this population.

Pregnancy and Lactation

See Pregnancy and Lactation section.

Pediatric Use

See Pediatric Uses section.

The duration of KT 150 mg/ml therapy depends on the underlying cause and severity of hypokalemia. It may be required short-term (e.g., during an episode of acute potassium loss from vomiting/diarrhea) or long-term (e.g., in patients on chronic non-potassium-sparing diuretic therapy). Treatment should continue only as long as clinically indicated, guided by periodic serum potassium monitoring, and reassessed regularly by the prescribing physician; it should not be continued indefinitely without follow-up.

Electrolyte Replenishers; Potassium Supplements; Minerals and Electrolytes

KT 150 mg/ml acts by directly supplying potassium and chloride ions to replenish body stores and restore normal serum potassium concentration. Potassium is essential for maintaining the resting membrane potential across cell membranes via the Na⁺/K⁺-ATPase pump, which is fundamental to normal neuromuscular excitability, cardiac conduction and contractility, and renal tubular function. By correcting a potassium deficit, KT 150 mg/ml restores normal electrophysiological function in excitable tissues, particularly cardiac and skeletal muscle, and helps maintain acid-base and fluid balance.

C

The use of KT 150 mg/ml in children is generally reserved for documented or high-risk hypokalemia and should be managed under pediatric specialist supervision. Pediatric oral dosing is typically individualized at approximately 1–4 mEq/kg/day (or by body surface area) in divided doses, adjusted to serum potassium levels. Safety and efficacy of extended-release tablet/capsule formulations of KT 150 mg/ml have not been specifically established in pediatric patients, partly due to tablet size and swallowing considerations; liquid or powder formulations may be preferred in younger children. Intravenous KT 150 mg/ml in children must be strictly individualized, diluted, and administered with continuous cardiac monitoring in a supervised setting.